ArticleActa paediatrica (Oslo, Norway : 1992)2026
Signs of Cross-Reactivity Between SARS-CoV-2 and Other Coronaviruses in a Pre-Vaccine Swedish School Setting.
Article in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
aimThis pilot study explored signs of immunological cross-reactivity between SARS-CoV-2 and human coronaviruses (HCoVs) in a Swedish school setting.
methodsA cross-sectional, hypothesis-generating study was conducted late 2020 before vaccines against COVID-19 were available. Forty-seven 7-8-year-old children, seventy-five 14-year-old adolescents, fifty-four 17-year-old adolescents, and 52 adult school staff were included, and immune responses to SARS-CoV-2 and HCoVs were assessed.
resultsThe SARS-CoV-2 seroprevalence was high in the older age groups (33%-41%). Seropositive individuals had significantly higher levels of antibodies against betacorona virus compared to seronegative individuals. SARS-CoV-2 seropositivity was rare among the 7-8-year-old children despite the high endemic context. SARS-CoV-2-specific T-cell responses in the absence of SARS-CoV-2-specific antibodies were seen in all age groups.
conclusionThe data support a role for cross-reactive immune responses induced by recent HCoV infections, with cross-reactive T-cell responses providing protection against COVID-19 in young children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.